Amplifying the Voice of the Whispering Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33653820.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4948.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nontargeted circulating tumor DNA (ctDNA) whole-genome sequencing is a novel strategy for genomic characterization of high-grade serous ovarian cancer. Changes in ctDNA levels are a sensitive indicator of disease burden with an average lead time of 6 months to clinical progression. This presents a unique opportunity to identify pathways driving progression as molecular vulnerabilities for clinical drug development.<i>See related article by Paracchini et al., p. 2549</i>.
Medical subject headings
- Circulating Tumor DNA
- Neoplasms